Stability and inactivation of SARS coronavirus
Identifieur interne : 005675 ( Main/Exploration ); précédent : 005674; suivant : 005676Stability and inactivation of SARS coronavirus
Auteurs : H. F. Rabenau [Allemagne] ; J. Cinatl [Allemagne] ; B. Morgenstern [Allemagne] ; G. Bauer [Allemagne] ; W. Preiser [Allemagne] ; H. W. Doerr [Allemagne]Source :
- Medical Microbiology and Immunology [ 0300-8584 ] ; 2005-01-01.
Descripteurs français
- KwdFr :
- Animaux, Cellules Vero (virologie), Coronavirus humain 229E (), Coronavirus humain 229E (croissance et développement), Coronavirus humain 229E (pathogénicité), Désinfectants (), Désinfectants (pharmacologie), Désinfection (), Humains, Température élevée, Virus du SRAS (), Virus du SRAS (croissance et développement), Virus du SRAS (pathogénicité).
- MESH :
- croissance et développement : Coronavirus humain 229E, Virus du SRAS.
- pathogénicité : Coronavirus humain 229E, Virus du SRAS.
- pharmacologie : Désinfectants.
- virologie : Cellules Vero.
- Animaux, Coronavirus humain 229E, Désinfectants, Désinfection, Humains, Température élevée, Virus du SRAS.
English descriptors
- KwdEn :
- Animals, Chlorocebus aethiops, Coronavirus 229E, Human (drug effects), Coronavirus 229E, Human (growth & development), Coronavirus 229E, Human (pathogenicity), Disinfectants (chemistry), Disinfectants (pharmacology), Disinfection, Disinfection (methods), Hot Temperature, Humans, SARS Virus (drug effects), SARS Virus (growth & development), SARS Virus (pathogenicity), SARS-associated coronavirus, Stability, Thermal inactivation, Vero Cells (virology), Virus infectivity.
- MESH :
- chemical , chemistry : Disinfectants.
- drug effects : Coronavirus 229E, Human, SARS Virus.
- growth & development : Coronavirus 229E, Human, SARS Virus.
- methods : Disinfection.
- pathogenicity : Coronavirus 229E, Human, SARS Virus.
- chemical , pharmacology : Disinfectants.
- virology : Vero Cells.
- Animals, Chlorocebus aethiops, Hot Temperature, Humans.
Abstract
Abstract : The SARS-coronavirus (SARS-CoV) is a newly emerged, highly pathogenic agent that caused over 8,000 human infections with nearly 800 deaths between November 2002 and September 2003. While direct person-to-person transmission via respiratory droplets accounted for most cases, other modes have not been ruled out. Faecal shedding is common and prolonged and has caused an outbreak in Hong Kong. We studied the stability of SARS-CoV under different conditions, both in suspension and dried on surfaces, in comparison with other human-pathogenic viruses, including human coronavirus HCoV-229E. In suspension, HCoV-229E gradually lost its infectivity completely while SARS-CoV retained its infectivity for up to 9 days; in the dried state, survival times were 24 h versus 6 days. Thermal inactivation at 56°C was highly effective in the absence of protein, reducing the virus titre to below detectability; however, the addition of 20% protein exerted a protective effect resulting in residual infectivity. If protein-containing solutions are to be inactivated, heat treatment at 60°C for at least 30 min must be used. Different fixation procedures, e.g. for the preparation of immunofluorescence slides, as well as chemical means of virus inactivation commonly used in hospital and laboratory settings were generally found to be effective. Our investigations confirm that it is possible to care for SARS patients and to conduct laboratory scientific studies on SARS-CoV safely. Nevertheless, the agent’s tenacity is considerably higher than that of HCoV-229E, and should SARS re-emerge, increased efforts need to be devoted to questions of environmental hygiene.
Url:
- https://api.istex.fr/ark:/67375/VQC-6JGNFX11-0/fulltext.pdf
- http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7086689
DOI: 10.1007/s00430-004-0219-0
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000075
- to stream Istex, to step Curation: 000075
- to stream Istex, to step Checkpoint: 001D53
- to stream Pmc, to step Corpus: 000428
- to stream Pmc, to step Curation: 000428
- to stream Pmc, to step Checkpoint: 001461
- to stream PubMed, to step Corpus: 002E26
- to stream PubMed, to step Curation: 002E26
- to stream PubMed, to step Checkpoint: 002469
- to stream Ncbi, to step Merge: 000781
- to stream Ncbi, to step Curation: 000781
- to stream Ncbi, to step Checkpoint: 000781
- to stream Main, to step Merge: 005B21
- to stream Main, to step Curation: 005675
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Stability and inactivation of SARS coronavirus</title><author><name sortKey="Rabenau, H F" sort="Rabenau, H F" uniqKey="Rabenau H" first="H. F." last="Rabenau">H. F. Rabenau</name></author><author><name sortKey="Cinatl, J" sort="Cinatl, J" uniqKey="Cinatl J" first="J." last="Cinatl">J. Cinatl</name></author><author><name sortKey="Morgenstern, B" sort="Morgenstern, B" uniqKey="Morgenstern B" first="B." last="Morgenstern">B. Morgenstern</name></author><author><name sortKey="Bauer, G" sort="Bauer, G" uniqKey="Bauer G" first="G." last="Bauer">G. Bauer</name></author><author><name sortKey="Preiser, W" sort="Preiser, W" uniqKey="Preiser W" first="W." last="Preiser">W. Preiser</name></author><author><name sortKey="Doerr, H W" sort="Doerr, H W" uniqKey="Doerr H" first="H. W." last="Doerr">H. W. Doerr</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:FBCE6183B48FE9531FBD76C7E9F6C3C562FEBAB6</idno><date when="2004" year="2004">2004</date><idno type="doi">10.1007/s00430-004-0219-0</idno><idno type="url">https://api.istex.fr/ark:/67375/VQC-6JGNFX11-0/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000075</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000075</idno><idno type="wicri:Area/Istex/Curation">000075</idno><idno type="wicri:Area/Istex/Checkpoint">001D53</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001D53</idno><idno type="wicri:doubleKey">0300-8584:2004:Rabenau H:stability:and:inactivation</idno><idno type="wicri:source">PMC</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7086689</idno><idno type="RBID">PMC:7086689</idno><idno type="wicri:Area/Pmc/Corpus">000428</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000428</idno><idno type="wicri:Area/Pmc/Curation">000428</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000428</idno><idno type="wicri:Area/Pmc/Checkpoint">001461</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">001461</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:15118911</idno><idno type="wicri:Area/PubMed/Corpus">002E26</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002E26</idno><idno type="wicri:Area/PubMed/Curation">002E26</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002E26</idno><idno type="wicri:Area/PubMed/Checkpoint">002469</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002469</idno><idno type="wicri:Area/Ncbi/Merge">000781</idno><idno type="wicri:Area/Ncbi/Curation">000781</idno><idno type="wicri:Area/Ncbi/Checkpoint">000781</idno><idno type="wicri:doubleKey">0300-8584:2004:Rabenau H:stability:and:inactivation</idno><idno type="wicri:Area/Main/Merge">005B21</idno><idno type="wicri:Area/Main/Curation">005675</idno><idno type="wicri:Area/Main/Exploration">005675</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Stability and inactivation of SARS coronavirus</title><author><name sortKey="Rabenau, H F" sort="Rabenau, H F" uniqKey="Rabenau H" first="H. F." last="Rabenau">H. F. Rabenau</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Institute for Medical Virology, Frankfurt am Main University Hospital Medical School, Paul Ehrlich-Strasse 40, 60596, Frankfurt am Main</wicri:regionArea><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Darmstadt</region><settlement type="city">Francfort-sur-le-Main</settlement></placeName></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Allemagne</country></affiliation></author><author><name sortKey="Cinatl, J" sort="Cinatl, J" uniqKey="Cinatl J" first="J." last="Cinatl">J. Cinatl</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Institute for Medical Virology, Frankfurt am Main University Hospital Medical School, Paul Ehrlich-Strasse 40, 60596, Frankfurt am Main</wicri:regionArea><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Darmstadt</region><settlement type="city">Francfort-sur-le-Main</settlement></placeName></affiliation></author><author><name sortKey="Morgenstern, B" sort="Morgenstern, B" uniqKey="Morgenstern B" first="B." last="Morgenstern">B. Morgenstern</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Institute for Medical Virology, Frankfurt am Main University Hospital Medical School, Paul Ehrlich-Strasse 40, 60596, Frankfurt am Main</wicri:regionArea><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Darmstadt</region><settlement type="city">Francfort-sur-le-Main</settlement></placeName></affiliation></author><author><name sortKey="Bauer, G" sort="Bauer, G" uniqKey="Bauer G" first="G." last="Bauer">G. Bauer</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Institute for Medical Virology, Frankfurt am Main University Hospital Medical School, Paul Ehrlich-Strasse 40, 60596, Frankfurt am Main</wicri:regionArea><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Darmstadt</region><settlement type="city">Francfort-sur-le-Main</settlement></placeName></affiliation></author><author><name sortKey="Preiser, W" sort="Preiser, W" uniqKey="Preiser W" first="W." last="Preiser">W. Preiser</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Institute for Medical Virology, Frankfurt am Main University Hospital Medical School, Paul Ehrlich-Strasse 40, 60596, Frankfurt am Main</wicri:regionArea><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Darmstadt</region><settlement type="city">Francfort-sur-le-Main</settlement></placeName></affiliation></author><author><name sortKey="Doerr, H W" sort="Doerr, H W" uniqKey="Doerr H" first="H. W." last="Doerr">H. W. Doerr</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Institute for Medical Virology, Frankfurt am Main University Hospital Medical School, Paul Ehrlich-Strasse 40, 60596, Frankfurt am Main</wicri:regionArea><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Darmstadt</region><settlement type="city">Francfort-sur-le-Main</settlement></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Medical Microbiology and Immunology</title><title level="j" type="abbrev">Med Microbiol Immunol</title><idno type="ISSN">0300-8584</idno><idno type="eISSN">1432-1831</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>Berlin/Heidelberg</pubPlace><date type="published" when="2005-01-01">2005-01-01</date><biblScope unit="volume">194</biblScope><biblScope unit="issue">1-2</biblScope><biblScope unit="page" from="1">1</biblScope><biblScope unit="page" to="6">6</biblScope></imprint><idno type="ISSN">0300-8584</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0300-8584</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Chlorocebus aethiops</term><term>Coronavirus 229E, Human (drug effects)</term><term>Coronavirus 229E, Human (growth & development)</term><term>Coronavirus 229E, Human (pathogenicity)</term><term>Disinfectants (chemistry)</term><term>Disinfectants (pharmacology)</term><term>Disinfection</term><term>Disinfection (methods)</term><term>Hot Temperature</term><term>Humans</term><term>SARS Virus (drug effects)</term><term>SARS Virus (growth & development)</term><term>SARS Virus (pathogenicity)</term><term>SARS-associated coronavirus</term><term>Stability</term><term>Thermal inactivation</term><term>Vero Cells (virology)</term><term>Virus infectivity</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Cellules Vero (virologie)</term><term>Coronavirus humain 229E ()</term><term>Coronavirus humain 229E (croissance et développement)</term><term>Coronavirus humain 229E (pathogénicité)</term><term>Désinfectants ()</term><term>Désinfectants (pharmacologie)</term><term>Désinfection ()</term><term>Humains</term><term>Température élevée</term><term>Virus du SRAS ()</term><term>Virus du SRAS (croissance et développement)</term><term>Virus du SRAS (pathogénicité)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Disinfectants</term></keywords><keywords scheme="MESH" qualifier="croissance et développement" xml:lang="fr"><term>Coronavirus humain 229E</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Coronavirus 229E, Human</term><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="growth & development" xml:lang="en"><term>Coronavirus 229E, Human</term><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Disinfection</term></keywords><keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Coronavirus 229E, Human</term><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Coronavirus humain 229E</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Désinfectants</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Disinfectants</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Cellules Vero</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Vero Cells</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Chlorocebus aethiops</term><term>Hot Temperature</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Coronavirus humain 229E</term><term>Désinfectants</term><term>Désinfection</term><term>Humains</term><term>Température élevée</term><term>Virus du SRAS</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract : The SARS-coronavirus (SARS-CoV) is a newly emerged, highly pathogenic agent that caused over 8,000 human infections with nearly 800 deaths between November 2002 and September 2003. While direct person-to-person transmission via respiratory droplets accounted for most cases, other modes have not been ruled out. Faecal shedding is common and prolonged and has caused an outbreak in Hong Kong. We studied the stability of SARS-CoV under different conditions, both in suspension and dried on surfaces, in comparison with other human-pathogenic viruses, including human coronavirus HCoV-229E. In suspension, HCoV-229E gradually lost its infectivity completely while SARS-CoV retained its infectivity for up to 9 days; in the dried state, survival times were 24 h versus 6 days. Thermal inactivation at 56°C was highly effective in the absence of protein, reducing the virus titre to below detectability; however, the addition of 20% protein exerted a protective effect resulting in residual infectivity. If protein-containing solutions are to be inactivated, heat treatment at 60°C for at least 30 min must be used. Different fixation procedures, e.g. for the preparation of immunofluorescence slides, as well as chemical means of virus inactivation commonly used in hospital and laboratory settings were generally found to be effective. Our investigations confirm that it is possible to care for SARS patients and to conduct laboratory scientific studies on SARS-CoV safely. Nevertheless, the agent’s tenacity is considerably higher than that of HCoV-229E, and should SARS re-emerge, increased efforts need to be devoted to questions of environmental hygiene.</div></front></TEI><affiliations><list><country><li>Allemagne</li></country><region><li>District de Darmstadt</li><li>Hesse (Land)</li></region><settlement><li>Francfort-sur-le-Main</li></settlement></list><tree><country name="Allemagne"><region name="Hesse (Land)"><name sortKey="Rabenau, H F" sort="Rabenau, H F" uniqKey="Rabenau H" first="H. F." last="Rabenau">H. F. Rabenau</name></region><name sortKey="Bauer, G" sort="Bauer, G" uniqKey="Bauer G" first="G." last="Bauer">G. Bauer</name><name sortKey="Cinatl, J" sort="Cinatl, J" uniqKey="Cinatl J" first="J." last="Cinatl">J. Cinatl</name><name sortKey="Doerr, H W" sort="Doerr, H W" uniqKey="Doerr H" first="H. W." last="Doerr">H. W. Doerr</name><name sortKey="Morgenstern, B" sort="Morgenstern, B" uniqKey="Morgenstern B" first="B." last="Morgenstern">B. Morgenstern</name><name sortKey="Preiser, W" sort="Preiser, W" uniqKey="Preiser W" first="W." last="Preiser">W. Preiser</name><name sortKey="Rabenau, H F" sort="Rabenau, H F" uniqKey="Rabenau H" first="H. F." last="Rabenau">H. F. Rabenau</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005675 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005675 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:FBCE6183B48FE9531FBD76C7E9F6C3C562FEBAB6
|texte= Stability and inactivation of SARS coronavirus
}}
| This area was generated with Dilib version V0.6.33. |  |